Macquarie Group Limited 13D and 13G filings for Ligand Pharmaceuticals Incorporated:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-01 4:07 pm Sale | 2024-09-30 | 13G | Ligand Pharmaceuticals Incorporated LGND | Macquarie Group Limited | 887,275 4.860% | -99,973 (-10.13%) | Filing |
| 2024-02-14 06:26 am Sale | 2023-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | Macquarie Group Limited | 987,248 5.660% | -14,577 (-1.46%) | Filing |
| 2022-02-14 10:39 am Sale | 2021-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | Macquarie Group Limited | 1,001,825 3.740% | -462,760 (-31.60%) | Filing |
| 2021-02-12 10:15 am Purchase | 2020-12-31 | 13G | Ligand Pharmaceuticals Incorporated LGND | Macquarie Group Limited | 1,464,586 5.680% | 1,464,586 (New Position) | Filing |